Stock Events

Stock Events

Liquidia Technologies 

€70.32
99
+€2.20+3.23% Wednesday 06:01

Statistics

Day High
0
Day Low
0
52W High
74.54
52W Low
14.01
Volume
0
Avg. Volume
25
Mkt Cap
6.25B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q1 2026
Next
0.35
0.45
0.56
0.66
Expected EPS
0.664535349
Actual EPS
N/A

Financials

-45.4%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
135.11MRevenue
-61.34MNet Income

Analyst Ratings

52.36Average Price Target
The highest estimate is 82.71.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
17%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LT4.MU. It's not an investment recommendation.
Amazon
21
AMZN
NVIDIA
21
NVDA
Alphabet
21
GOOGL
Microsoft
19
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Innoviva
INVA
Mkt Cap1.64B
Innoviva focuses on the development and commercialization of pharmaceuticals, directly competing in the respiratory and pulmonary market similar to Liquidia's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is involved in creating therapies for cystic fibrosis, a direct competition to Liquidia's pulmonary disease treatments.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline produces a wide range of pharmaceuticals, including treatments for respiratory diseases, directly competing with Liquidia's product offerings.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca is a global biopharmaceutical company focusing on various therapeutic areas, including respiratory diseases, making it a competitor to Liquidia.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. offers a broad portfolio of drugs, including treatments for respiratory conditions, competing in the same space as Liquidia.
Pfizer
PFE
Mkt Cap137.76B
Pfizer develops and manufactures drugs and vaccines, including for respiratory diseases, positioning it as a competitor to Liquidia.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on advanced therapies for serious diseases, including pulmonary conditions, making it a competitor in the same therapeutic area as Liquidia.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is known for its innovative treatments in several areas, including respiratory diseases, competing with Liquidia's developments.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including for respiratory conditions, making it a competitor to Liquidia.
Novartis
NVS
Mkt Cap293.94B
Novartis focuses on a wide range of healthcare areas, including respiratory diseases, directly competing with Liquidia's therapeutic focus.

About

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Show more...
CEO
Dr. Roger A. Jeffs Ph.D.
Employees
216
Country
United States

Listings

MU
DE
LT4.MU
STU
DE
LT4.STU
XNAS
US
LQDA
F
DE
LT4.F

0 Comments

Share your thoughts

FAQ

What is Liquidia Technologies stock price today?▼
The current price of LT4.MU is €70.32 EUR — it has increased by +3.23% in the past 24 hours. Watch Liquidia Technologies stock price performance more closely on the chart.
What is Liquidia Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Liquidia Technologies stocks are traded under the ticker LT4.MU.
What is Liquidia Technologies market cap?▼
Today Liquidia Technologies has the market capitalization of 6.25B
When is the next Liquidia Technologies earnings date?▼
Liquidia Technologies is going to release the next earnings report on August 06, 2026.
What were Liquidia Technologies earnings last quarter?▼
LT4.MU earnings for the last quarter are 0.44 EUR per share, whereas the estimation was 0.35 EUR resulting in a +26.78% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Liquidia Technologies revenue for the last year?▼
Liquidia Technologies revenue for the last year amounts to 135.11M EUR.
What is Liquidia Technologies net income for the last year?▼
LT4.MU net income for the last year is -61.34M EUR.
How many employees does Liquidia Technologies have?▼
As of July 23, 2026, the company has 216 employees.
In which sector is Liquidia Technologies located?▼
Liquidia Technologies operates in the Health & Wellness sector.
When did Liquidia Technologies complete a stock split?▼
Liquidia Technologies has not had any recent stock splits.
Where is Liquidia Technologies headquartered?▼
Liquidia Technologies is headquartered in Morrisville, United States.